2008•Expert Opinion on Drug DeliveryRequires access

Crystallisation within transdermal rotigotine patch: is there cause for concern?

К. Ray Chaudhuri

Abstract

1. Rotigotine transdermal patch is the first transdermal non-ergot dopamine agonist, being a selective dopamine D1/D2/D3 receptor agonist [1-4]. Rotigotine patch is effective over 24 h and provides...

About this research paper

What this paper is about

Why it matters

OpenAlex reports 57 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Rotigotine, Transdermal patch, Transdermal, Agonist, Dopamine agonist, Pharmacology, Medicine, Dopamine receptor D2

Back to paper search Browse research topics Original source

Crystallisation within transdermal rotigotine patch: is there cause for concern? — Research Paper | ScholarLens